Exporting Cannabis from Canada to Israel in 2026: What Canadian LPs Need to Know

Israel's medical cannabis import framework is governed by the Israel Medical Cannabis Agency, operating under the Ministry of Health. IMCA enforces a tiered quality standards regime covering cultivation practices and post-harvest manufacturing separately. The split matters because the certification requirements differ at each stage.

IMC-GMP and IMC-GAP: the two standards

For cultivation and primary processing, IMCA accepts IMC-GAP certification. IMC-GAP is aligned with GACP principles from the European Medicines Agency and the WHO. Canadian LPs can satisfy IMC-GAP requirements through recognized third-party certifying bodies, including Control Union (CUMCS-GAP) and IQC (ICANN-GAP). This makes Israel more accessible than markets requiring full EU-GMP at the cultivation stage.

For post-harvest processing and packaging, IMCA requires either IMC-GMP certification or EU-GMP equivalency. Health Canada's Good Production Practices (GPP) framework does not automatically satisfy IMC-GMP or EU-GMP for post-harvest facilities. That's the gap most Canadian LPs miss. Check your post-harvest certification status before committing to a supply timeline.

ISO 17025 testing requirements

Every batch exported to Israel must be supported by a Certificate of Analysis from an ISO/IEC 17025-accredited laboratory. The COA must cover cannabinoid potency, microbial limits, residual solvents, pesticide residues, and heavy metals. IMCA documentation requirements align closely with what Health Canada mandates under the Cannabis Regulations, which reduces the documentation burden for LPs already in full Canadian compliance.

Under the Cannabis Act and the Cannabis Regulations, a Canadian LP must hold a valid export permit issued by Health Canada before any shipment leaves the country. The permit is batch-specific and destination-specific. It cannot be reused across multiple shipments or multiple importers.

The five-step Canada-Israel export pathway

1. Confirm the Israeli importer holds a current IMCA import licence. IMCA issues import licences to approved pharmaceutical distributors. Without a valid licence on the Israeli side, Health Canada will not issue the Canadian export permit.
2. Obtain the Israeli narcotic import permit. Cannabis is a controlled substance under the Israeli Dangerous Drugs Ordinance. The importer applies to the Israeli Ministry of Health for a narcotic import permit specifying quantity, strain, cannabinoid profile, and batch identifiers. This step precedes the Canadian application.
3. Submit the Health Canada export permit application. The application references the Israeli import permit, names the importing party, specifies product and quantity, and confirms the shipment route. Allow four to six weeks minimum for standard processing.
4. Complete batch release and compile shipment documentation. The shipment package includes the COA, export permit, a phytosanitary certificate from the Canadian Food Inspection Agency (CFIA) where required, customs declarations, and carrier-specific dangerous goods paperwork.
5. Book temperature-controlled freight. Dried flower must maintain controlled temperature and humidity throughout transit. Confirm freight before batch release. Delays after release eat into shelf life and can jeopardise the batch at the Israeli customs stage.

The 2026 anti-dumping context

The July 2026 investigation, filed by Israeli domestic cultivators Evergreen Solomon Pharma and Trichome Ltd., targets Canadian pricing during 2025. It's a trade remedy case, not a quality action. Canadian LPs exporting at commodity pricing with thin documentation are exposed. LPs with premium positioning, differentiated product specs, and a full compliance file are not the target of this complaint. The distinction is real and documentable.

Israeli pharmaceutical distributors treat supplier qualification as a compliance process. The commercial conversation comes second. Understanding what they're actually checking saves time and prevents late-stage disqualifications.

Documentation package

Distributors require a complete documentation package before approving any supply relationship. This means: current IMC-GAP certification (or EU-GMP equivalent), ISO/IEC 17025 COA for each batch, a Certificate of Analysis from the Canadian production facility, a Letter of Authorization from the exporting LP, and evidence of Health Canada LP licence status. Many also request a Product Dossier covering genetics, cultivation inputs, post-harvest process, and packaging specifications.

Batch consistency and traceability

Israeli importers need to demonstrate to IMCA that each imported batch matches the specification registered at import permit stage. Batch-to-batch consistency in cannabinoid potency and terpene profile reduces re-registration burden on the importer's side. Full traceability from cultivation lot to final packaged unit is expected. For context on evaluating COA data, see our guide to cannabis certificates of analysis for B2B buyers.

Supply reliability and lead times

First-shipment lead times typically run six to ten weeks from supply agreement to delivery. Distributors factor this into inventory planning, and late or inconsistent permit timelines create stock gaps that affect their pharmacy relationships. Canadian LPs that can demonstrate predictable availability are worth more than cheaper suppliers who can't.

Product format and packaging

Israeli pharmacy-grade supply requires finished, packaged flower meeting Israeli labelling requirements and the product specification filed with IMCA. Large-bud format, hand-trimmed flower carries premium positioning in the Israeli medical channel. Packaging must be sealed, tamper-evident, and carry batch-level traceability markings. Visual consistency across batches matters to pharmacy buyers, not just regulators.

AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain ISO/IEC 17025-tested batch data, full traceability records, and the compliance documentation that IMCA-licensed Israeli importers need for supplier qualification. Our refined genetics and consistent cannabinoid profiles support the batch-level specification matching that keeps permit re-registration straightforward. For an overview of how our quality standards align with European GMP frameworks, see our EU-GMP certification guide for Canadian LPs.

For Israeli distributors qualifying Canadian supply partners in 2026, AlphaLeaf's position is clear: premium indoor cultivation, batch consistency, and a compliance file ready for review. Canadian LPs competing on price in the current anti-dumping environment face real commercial and regulatory headwinds. Supply built on quality documentation, certified production practices, and consistent product specifications is the sustainable path into the Israeli medical channel. That's the differentiator. Not price.

To discuss supply terms, certifications, and first-shipment timelines, contact us through our international enquiries page or visit the international partnerships section.

Does Health Canada allow cannabis exports to Israel?

Yes. Health Canada issues export permits for cannabis to Israel under the Cannabis Act and Cannabis Regulations. Israel is one of Canada's established cannabis export destinations and an approved jurisdiction under IMCA's import framework. Each export permit is batch-specific and requires a corresponding Israeli narcotic import permit before it can be issued.

Does Health Canada GPP satisfy Israeli IMC-GMP requirements?

Not automatically. IMCA operates its own standards framework: IMC-GAP for cultivation and IMC-GMP for manufacturing and post-harvest processing. Health Canada's Good Production Practices (GPP) aligns with IMC-GAP in principle, but Canadian post-harvest facilities need to assess whether their certifications are accepted by IMCA directly or require supplementary third-party certification such as CUMCS-GAP from Control Union.

What is the typical first-shipment lead time to Israel?

First-shipment lead times typically run six to ten weeks from supply agreement to delivery, accounting for IMCA import permit processing, Health Canada export permit review, batch release, freight booking, and Israeli customs clearance. Established supply relationships with pre-approved importers can reduce this on subsequent shipments once the permit framework is in place.

How does the July 2026 anti-dumping investigation affect Canadian LP exports?

The investigation targets pricing on imports from Canadian producers covering January to December 2025. It is a trade remedy investigation, not a product quality or regulatory action. Canadian LPs supplying at premium price points with full documentation and differentiated product specifications are less exposed to anti-dumping findings than commodity-volume suppliers. The investigation does not suspend or restrict ongoing export permits during the review period.

What documentation does an Israeli importer need from a Canadian LP?

Israeli importers typically require: current IMC-GAP or EU-GMP certification for the exporting facility, an ISO/IEC 17025 COA for each batch, evidence of Health Canada LP licensing, a Letter of Authorization from the exporting LP, and a Product Dossier covering genetics, cultivation practices, and post-harvest handling. Some importers also require batch-level traceability documentation from cultivation lot through to final packaged unit.